Table Info

Table 1.

Characteristics of the patients

Characteristic	n = 10 (mean ± SEM)
Age, year	59.3 ± 6.1
Age at diagnosis, year	53.3 ± 6.4
Duration of illness, year	6.0 ± 1.2
Sex, male/female, n	2/8
Biologic agents, n^†	Mepolizumab, 10 Benralizumab, 1 Dupilumamb, 0
Duration to biologic initiation, month	39.9 ± 12.6
Duration of treatment with biologics, month	37.4 ± 7.8
Clinical manifestations
Asthma, n	10
Asthma severity (GINA) Step1/2/3/4/5, n	0/0/2/2/6
Neuropathy, n	9
Cutaneous, n	7
Cardiomyopathy, n	2
Cerebrovascular disease, n	1
Fever, n	2
Positive for ANCA, n	2
Treatment
Corticosteroids, n	10
Corticosteroid doses at baseline, mg/day	24.7 ± 4.9
Methylprednisolone pulse therapy, n	5
Immunosuppressive agents, n	1
Intravenous cyclophosphamide pulse therapy, n	2
IVIg, n	3
EGPA severity
Severe, n	10

GINA: Global Initiative for Asthma; ANCA: anti-neutrophil cytoplasmic antibody; IVIg: intravenous immunoglobulin; SEM: standard error of the mean; ^† As one patient received both mepolizumab and benralizumab, the sum of patients was set to 11

Supplementary materials

The supplementary figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/100958_sup_1.pdf.

Declarations

Acknowledgments

We thank Minako Muraji and Mizuki Morishita for their assistance with data collection, and Tammy Bicket for English language editing.

Author contributions

TM: Conceptualization, Investigation, Methodology, Writing—original draft. HM and YD: Investigation, Resources, Writing—review & editing. MO: Visualization. K Tsuruzono, HU, SY, TS, JI and K Machida: Resources. KK and K Mizuno: Project administration. K Takagi and K Tanaka: Writing—review & editing. HI: Project administration, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

HI reports research/educational grants from Boehringer-Ingelheim, GlaxoSmithKline, and OMRON, and payment or honoraria for lectures/advisory committees from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, Novartis and Sanofi. K Tanaka reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Daiichi Sankyo, Eli Lilly, Merck, Pfizer, Takeda Pharmaceutical, MSD, Bristol Myers Squibb and Novartis. However, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript for this study. The other authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the Institutional Review Board of Kagoshima University (No.190118). The study was also conducted in accordance with the ethical principles of the Declaration of Helsinki.

Consent to participate

The informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The datasets for this manuscript are not publicly available because of ethical reasons. Requests for accessing the datasets should be directed to the corresponding author Dr. Hiromasa Inoue, inoue@m2.kufm.kagoshima-u.ac.jp.

Funding

Not applicable.

Copyright

References

Fogo AB, Cohen AH, Colvin RB, Jennette JC, Alpers CE. Crescentic Glomerulonephritis and Vasculitis. In: Fogo AB, Cohen AH, Colvin RB, Jennette JC, Alpers CE, editors. Fundamentals of Renal Pathology. Berlin, Heidelberg: Springer; 2014. pp. 107-22.

White J, Dubey S. Eosinophilic granulomatosis with polyangiitis: A review. Autoimmun Rev. 2023;22:103219. [DOI] [PubMed]

Fijolek J, Radzikowska E. Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment. Front Med (Lausanne). 2023;10:1145257. [DOI] [PubMed] [PMC]

Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19:378–93. [DOI] [PubMed]

Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al.; EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376:1921–32. [DOI] [PubMed] [PMC]

Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, et al. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis. J Allergy Clin Immunol Pract. 2021;9:1186–93.e1. [DOI] [PubMed]

Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A, et al. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study. Front Immunol. 2023;14:1204444. [DOI] [PubMed] [PMC]

Sada KE, Kojo Y, Fairburn-Beech J, Sato K, Akiyama S, Van Dyke MK, et al. The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan: a retrospective, descriptive cohort claims database study. Mod Rheumatol. 2022;32:380–6. [DOI] [PubMed]

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827–32. [DOI] [PubMed]

10.

Kitamura N, Hamaguchi M, Nishihara M, Ikumi N, Sugiyama K, Nagasawa Y, et al. The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients. Allergol Int. 2021;70:148–9. [DOI] [PubMed]

11.

Ueno M, Miyagawa I, Nakano K, Iwata S, Hanami K, Fukuyo S, et al. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther. 2021;23:86. [DOI] [PubMed] [PMC]

12.

Canzian A, Venhoff N, Urban ML, Sartorelli S, Ruppert AM, Groh M, et al.; French Vasculitis Study Group and the European EGPA Study Group. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. Arthritis Rheumatol. 2021;73:498–503. [DOI] [PubMed]

13.

Ríos-Garcés R, Prieto-González S, Hernández-Rodríguez J, Arismendi E, Alobid I, Penatti AE, et al. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. Eur J Intern Med. 2022;95:61–6. [DOI] [PubMed]

14.

Nakamura Y, Fukutomi Y, Sekiya K, Kajiwara K, Kawasaki Y, Fujita N, et al. Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis. Mod Rheumatol. 2022;32:387–95. [DOI] [PubMed]

15.

Bettiol A, Urban ML, Dagna L, Cottin V, Franceschini F, Del Giacco S, et al.; European EGPA Study Group. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis Rheumatol. 2022;74:295–306. [DOI] [PubMed] [PMC]

16.

Özdel Öztürk B, Yavuz Z, Aydın Ö, Mungan D, Sin BA, Demirel YS, et al. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience. Int Arch Allergy Immunol. 2022;183:1281-90. [DOI] [PubMed]

17.

Yamane T, Hashiramoto A. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan. Arthritis Res Ther. 2023;25:110. [DOI] [PubMed] [PMC]

18.

Matsuno O. Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy. Int Arch Allergy Immunol. 2024;185:116–23. [DOI] [PubMed]

19.

Ishii T, Kunishige H, Kobayashi T, Hayashi E, Komatsubara M, Ishii T, et al. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: A 48-week interim analysis of the MARS study. Mod Rheumatol. 2024;34:978-87. [DOI] [PubMed]

20.

Cottu A, Groh M, Desaintjean C, Marchand-Adam S, Guillevin L, Puechal X, et al.; French Vasculitis Study Group. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2023;82:1580–6. [DOI] [PubMed]

21.

Bettiol A, Urban ML, Padoan R, Groh M, Lopalco G, Egan A, et al.; European EGPA Study Group. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. Lancet Rheumatol. 2023;5:e707–15. [DOI] [PubMed]

22.

Nanzer AM, Maynard-Paquette AC, Alam V, Green L, Thomson L, Lam J, et al. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis. J Allergy Clin Immunol Pract. 2024;12:724–32. [DOI] [PubMed]

23.

Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, et al.; MANDARA Study Group. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2024;390:911–21. [DOI] [PubMed]

24.

Painter MW, Brosius Lutz A, Cheng YC, Latremoliere A, Duong K, Miller CM, et al. Diminished Schwann cell repair responses underlie age-associated impaired axonal regeneration. Neuron. 2014;83:331–43. [DOI] [PubMed] [PMC]

25.

Nocera G, Jacob C. Mechanisms of Schwann cell plasticity involved in peripheral nerve repair after injury. Cell Mol Life Sci. 2020;77:3977–89. [DOI] [PubMed] [PMC]

26.

Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143:1742–51.e7. [DOI] [PubMed]

27.

Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, et al. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021;9:4381–92.e4. [DOI] [PubMed]

28.

Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121–31. [DOI] [PubMed]

29.

Jakiela B, Szczeklik W, Plutecka H, Sokolowska B, Mastalerz L, Sanak M, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford). 2012;51:1887–93. [DOI] [PubMed]

30.

Biedroń G, Włudarczyk A, Wawrzycka-Adamczyk K, Wójcik K, Sznajd J, Zdrojewski Z, et al. Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data. Adv Med Sci. 2020;65:156–62. [DOI] [PubMed]

31.

Global Initiative for Asthma [Internet]. Bethesda: GINA; c2023 [cited 2024 Mar 7]. Global strategy for asthma management and prevention 2023. Available from: http://ginasthma.org

32.

Durel CA, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken). 2016;68:374–87. [DOI] [PubMed]